Anti-human IL-6 (Siltuximab Biosimilar) Research Grade
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Siltuximab, making it ideal for research applications. It specifically targets human interleukin-6 (IL-6), a 21–28 kDa cytokine produced by a wide range of cells, including T cells, B cells, monocytes, fibroblasts, and endothelial cells. IL-6 exerts its effects through a type I cytokine receptor complex composed of the IL-6 receptor alpha chain (IL-6Rα, also known as CD126) and the signal-transducing subunit gp130 (CD130). Upon binding to its receptor complex, IL-6 regulates antigen-specific immune responses, drives inflammatory pathways, contributes to neuronal development, and plays a critical role in the acute phase response. Siltuximab binds directly to IL-6, blocking its interaction with both soluble and membrane-bound IL-6R, thereby preventing downstream signaling.
Specifications
Product name: Anti-human IL-6 (Siltuximab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: Human IgG1, κ
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
Molecular Weight: 150 kDa
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Siltuximab, making it ideal for research applications. It specifically targets human interleukin-6 (IL-6), a 21–28 kDa cytokine produced by a wide range of cells, including T cells, B cells, monocytes, fibroblasts, and endothelial cells. IL-6 exerts its effects through a type I cytokine receptor complex composed of the IL-6 receptor alpha chain (IL-6Rα, also known as CD126) and the signal-transducing subunit gp130 (CD130). Upon binding to its receptor complex, IL-6 regulates antigen-specific immune responses, drives inflammatory pathways, contributes to neuronal development, and plays a critical role in the acute phase response. Siltuximab binds directly to IL-6, blocking its interaction with both soluble and membrane-bound IL-6R, thereby preventing downstream signaling.
Specifications
Product name: Anti-human IL-6 (Siltuximab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: Human IgG1, κ
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
Molecular Weight: 150 kDa
Amount: 100ug
Product Details
This non-therapeutic biosimilar antibody utilizes the same variable regions as the therapeutic antibody Siltuximab, making it ideal for research applications. It specifically targets human interleukin-6 (IL-6), a 21–28 kDa cytokine produced by a wide range of cells, including T cells, B cells, monocytes, fibroblasts, and endothelial cells. IL-6 exerts its effects through a type I cytokine receptor complex composed of the IL-6 receptor alpha chain (IL-6Rα, also known as CD126) and the signal-transducing subunit gp130 (CD130). Upon binding to its receptor complex, IL-6 regulates antigen-specific immune responses, drives inflammatory pathways, contributes to neuronal development, and plays a critical role in the acute phase response. Siltuximab binds directly to IL-6, blocking its interaction with both soluble and membrane-bound IL-6R, thereby preventing downstream signaling.
Specifications
Product name: Anti-human IL-6 (Siltuximab Biosimilar) Research Grade
Species: Human
Storage condition: 4°C for short term; -20°C for long term
Note: For research use only. Not suitable for human use
Isotype: Human IgG1, κ
Clonality: Monoclonal Antibody
Purity: >95% Determined by SDS-PAGE
Sterility: 0.2 µm filtration
Purification: Protein A
Molecular Weight: 150 kDa